Fluorescent Probes with Unnatural Amino Acids to Monitor Proteasome Activity in Real-Time

被引:29
作者
Zerfas, Breanna L. [1 ]
Coleman, Rachel A. [1 ]
Salazar-Chaparro, Andres F. [1 ]
Macatangay, Nathaniel J. [1 ]
Trader, Darci J. [1 ]
机构
[1] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA
关键词
INHIBITOR; 20S; PATHWAY; DISCOVERY; CANCER; POTENT;
D O I
10.1021/acschembio.0c00634
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The proteasome is an essential protein complex that, when dysregulated, can result in various diseases in eukaryotic cells. As such, understanding the enzymatic activity of the proteasome and what can alter it is crucial to elucidating its roles in these diseases. This can be done effectively by using activity-based fluorescent substrate probes, of which there are many commercially available that target the individual protease-like subunits in the 20S CP of the proteasome. Unfortunately, these probes have not displayed appropriate characteristics for their use in live cell-based assays. In the work presented here, we have developed a set of probes which have shown improved fluorescence properties and selectivity toward the proteasome compared to other cellular proteases. By including unnatural amino acids, we have found probes which can be utilized in various applications, including monitoring the effects of small molecule stimulators of the proteasome in live cells and comparing the relative proteasome activity across different cancer cell types. In future studies, we expect the fluorescent probes presented here will serve as tools to support the discovery and characterization of small molecule modulators of proteasome activity.
引用
收藏
页码:2588 / 2596
页数:9
相关论文
共 46 条
  • [1] Potential for proteasome inhibition in the treatment of cancer
    Adams, J
    [J]. DRUG DISCOVERY TODAY, 2003, 8 (07) : 307 - 315
  • [2] The proteasome: structure, function, and role in the cell
    Adams, J
    [J]. CANCER TREATMENT REVIEWS, 2003, 29 : 3 - 9
  • [3] Development of the proteasome inhihitor Veleade™ (Bortezomib)
    Adams, J
    Kauffman, M
    [J]. CANCER INVESTIGATION, 2004, 22 (02) : 304 - 311
  • [4] The proteasome: a novel target for cancer chemotherapy
    Almond, JB
    Cohen, GM
    [J]. LEUKEMIA, 2002, 16 (04) : 433 - 443
  • [5] Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib
    Berkers, CR
    Verdoes, M
    Lichtman, E
    Fiebiger, E
    Kessler, BM
    Anderson, KC
    Ploegh, HL
    Ovaa, H
    Galardy, PJ
    [J]. NATURE METHODS, 2005, 2 (05) : 357 - 362
  • [6] Role of the proteasome in Alzheimer's disease
    Checler, F
    da Costa, CA
    Ancolio, K
    Chevallier, N
    Lopez-Perez, E
    Marambaud, P
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2000, 1502 (01): : 133 - 138
  • [7] BIOGENESIS, STRUCTURE AND FUNCTION OF THE YEAST 20S PROTEASOME
    CHEN, P
    HOCHSTRASSER, M
    [J]. EMBO JOURNAL, 1995, 14 (11) : 2620 - 2630
  • [8] Overexpression of proteasome β5 subunit increases the amount of assembled proteasome and confers ameliorated response to oxidative stress and higher survival rates
    Chondrogianni, N
    Tzavelas, C
    Pemberton, AJ
    Nezis, IP
    Rivett, AJ
    Gonos, ES
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (12) : 11840 - 11850
  • [9] Methods to Discover and Evaluate Proteasome Small Molecule Stimulators
    Coleman, Rachel A.
    Trader, Darci J.
    [J]. MOLECULES, 2019, 24 (12):
  • [10] All About the Core: A Therapeutic Strategy to Prevent Protein Accumulation with Proteasome Core Particle Stimulators
    Coleman, Rachel A.
    Trader, Darci J.
    [J]. ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2018, 1 (02) : 140 - 142